| First Author | Cheng J | Year | 2023 |
| Journal | Cell Metab | Volume | 35 |
| Issue | 6 | Pages | 961-978.e10 |
| PubMed ID | 37178684 | Mgi Jnum | J:336653 |
| Mgi Id | MGI:7491414 | Doi | 10.1016/j.cmet.2023.04.017 |
| Citation | Cheng J, et al. (2023) Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8(+) T cells in the tumor microenvironment. Cell Metab 35(6):961-978.e10 |
| abstractText | Metabolic alterations in the microenvironment significantly modulate tumor immunosensitivity, but the underlying mechanisms remain obscure. Here, we report that tumors depleted of fumarate hydratase (FH) exhibit inhibition of functional CD8(+) T cell activation, expansion, and efficacy, with enhanced malignant proliferative capacity. Mechanistically, FH depletion in tumor cells accumulates fumarate in the tumor interstitial fluid, and increased fumarate can directly succinate ZAP70 at C96 and C102 and abrogate its activity in infiltrating CD8(+) T cells, resulting in suppressed CD8(+) T cell activation and anti-tumor immune responses in vitro and in vivo. Additionally, fumarate depletion by increasing FH expression strongly enhances the anti-tumor efficacy of anti-CD19 CAR T cells. Thus, these findings demonstrate a role for fumarate in controlling TCR signaling and suggest that fumarate accumulation in the tumor microenvironment (TME) is a metabolic barrier to CD8(+) T cell anti-tumor function. And potentially, fumarate depletion could be an important strategy for tumor immunotherapy. |
